Literature DB >> 27241921

Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location.

P Kulig1, M Sierzega1, R Pach1, P Kolodziejczyk1, J Kulig2.   

Abstract

BACKGROUND: The anatomical Siewert classification for adenocarcinoma of the oesophagogastric junction (OGJ) was dictated by the potential differences in tumour epidemiology and pathology. However, there are some uncertainties whether the distinction of true carcinoma of the cardia (type II) and subcardial gastric cancer (type III) is of clinical value.
METHODS: Using a multicentre data set, we studied 243 patients with OGJ adenocarcinomas who underwent gastric resections between 1998 and 2008. Postoperative complications and long-term survival were compared to evaluate the potential differences in clinically relevant outcomes.
RESULTS: A group of 109 patients with Siewert type II and 134 with Siewert type III OGJ adenocarcinoma was identified. Both groups showed similar baseline characteristics, including clinical symptoms and duration of diagnostic delay. However, the prevalence of node-negative cancers and superficial (T1-T2) lesions was significantly higher among type II tumours, i.e. 42% vs 21% (P = 0.003) and 43% vs 20% (P = 0.045), respectively. Morbidity and mortality rates were 25% and 3.7%, respectively, but types and incidence of postoperative complications were not affected by the anatomical location of the tumour. The overall median survival was significantly longer for Siewert type II tumours (42 vs 16 months; P < 0.001). However, only patients' age >70 years, depth of tumour infiltration, lymph node metastases, distant metastases, and radical resection were identified as independent prognostic factors using the Cox proportional hazards model.
CONCLUSION: The topographic-anatomic sub-classification of OGJ adenocarcinomas does not correspond to relevant differences in clinical parameters of safety and efficacy of surgical treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma of the oesophagogastric junction; Gastric cancer; Prognosis; Siewert classification

Mesh:

Year:  2016        PMID: 27241921     DOI: 10.1016/j.ejso.2016.04.061

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Outcomes of the Surgical Treatment for Adenocarcinoma of the Cardia - Single Institution Experience.

Authors:  Stojan Potrc; Arpad Ivanecz; Bojan Krebs; Urska Marolt; Bojan Iljevec; Tomaz Jagric
Journal:  Radiol Oncol       Date:  2017-09-14       Impact factor: 2.991

2.  Optimal Extent of Transhiatal Gastrectomy and Lymphadenectomy for the Stomach-Predominant Adenocarcinoma of Esophagogastric Junction: Retrospective Single-Institution Study in China.

Authors:  Baoyu Zhao; Zhenzhan Zhang; Debin Mo; Yiming Lu; Yanfeng Hu; Jiang Yu; Hao Liu; Guoxin Li
Journal:  Front Oncol       Date:  2019-01-21       Impact factor: 6.244

3.  Conventional regression analysis and machine learning in prediction of anastomotic leakage and pulmonary complications after esophagogastric cancer surgery.

Authors:  Robert T van Kooten; Renu R Bahadoer; Bouwdewijn Ter Buurkes de Vries; Michel W J M Wouters; Rob A E M Tollenaar; Henk H Hartgrink; Hein Putter; Johan L Dikken
Journal:  J Surg Oncol       Date:  2022-05-03       Impact factor: 2.885

4.  Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.

Authors:  Michael Thomaschewski; Richard Hummel; Ekaterina Petrova; Juliana Knief; Ulrich Friedrich Wellner; Tobias Keck; Dirk Bausch
Journal:  World J Gastroenterol       Date:  2018-04-07       Impact factor: 5.742

5.  Simultaneous resection of an adenocarcinoma of the cardia and a synchronous adenocarcinoma of the sigmoid: Report of a case.

Authors:  Giulio Illuminati; Bruno Perotti; Giulia Pizzardi; Rocco Pasqua; Gianpaolo Prezioso; Monica Schiratti; Alberto Angelici
Journal:  Ann Med Surg (Lond)       Date:  2018-08-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.